{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:12:44Z","timestamp":1753891964648,"version":"3.41.2"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T00:00:00Z","timestamp":1641168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Introduction:<\/jats:bold> Some encouraging findings of Chinese herbal medicine (CHM) in management of idiopathic membranous nephropathy (IMN) obtained in the setting of clinical trials are hard to validate in the daily clinical practice due to a complicated treatment scenario of CHM in practice. The primary objective of this registry is to provide a description of treatment patterns used in management of IMN and assess clinical remission in daily practice in a Chinese population sample with IMN.<\/jats:p><jats:p><jats:bold>Methods and analysis:<\/jats:bold> This is a prospective, multicenter cohort which will comprise 2000 adults with IMN regardless of urinary protein levels that will be recruited from 11 nephrology centers across China. The participants will be followed for up to at least 2\u00a0years. Primary outcome is composite remission (either complete remission or partial remission) 24\u00a0months after enrolment. The secondary outcomes are complete remission, partial remission, time to remission, no response, relapse, proteinuria, annual change of glomerular filtration rate, antibodies against PLA2R, and composite endpoint of 40% reduction of glomerular filtration rate, doubling of serum creatinine, end-stage renal disease, and death. Propensity score analysis will be used for matching and adjustment.<\/jats:p><jats:p><jats:bold>Ethics and dissemination:<\/jats:bold> This study has been approved by the Ethics Committee of Guangdong Provincial Hospital of Chinese Medicine (BF2020-094-01). Results of the study will be published in both national and international peer-reviewed journals, and presented at scientific conferences. Investigators will inform the participants as well as other IMN patients of the findings via health education.<\/jats:p><jats:p><jats:bold>Study registration<\/jats:bold>: ChiCTR2000033680 (prospectively registered).<\/jats:p>","DOI":"10.3389\/fphar.2021.760482","type":"journal-article","created":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T08:52:34Z","timestamp":1641199954000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-World Effects of Chinese Herbal Medicine for Idiopathic Membranous Nephropathy (REACH-MN): Protocol of a Registry-Based Cohort Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Lihong","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xing","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weizhong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinfeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1053\/j.ajkd.2007.07.032","article-title":"Treatment of Idiopathic Membranous Nephropathy with the Herb Astragalus Membranaceus","volume":"50","author":"Ahmed","year":"2007","journal-title":"Am. J. Kidney Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1053\/j.ajkd.2013.06.002","article-title":"KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"62","author":"Beck","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1053\/j.ajkd.2013.05.005","article-title":"Efficacy and Safety of Traditional Chinese Medicine (Shenqi Particle) for Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Controlled Clinical Trial","volume":"62","author":"Chen","year":"2013","journal-title":"Am. J. Kidney Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"Cd004293","DOI":"10.1002\/14651858.CD004293.pub3","article-title":"Immunosuppressive Treatment for Idiopathic Membranous Nephropathy in Adults with Nephrotic Syndrome","volume":"2014","author":"Chen","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/cjn.11761116","article-title":"Primary Membranous Nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.kint.2018.10.018","article-title":"Management and Treatment of Glomerular Diseases (Part 1): Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"95","author":"Floege","year":"2019","journal-title":"Kidney Int."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race","volume":"385","author":"Inker","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"B8","unstructured":"ISO 20498-1: 2019: Traditional Chinese Medicine-Computerized Tongue Image Analysis System - Part 1: General Requirements2019"},{"key":"B9","unstructured":"ISO\/TS 20498-3:2020 Traditional Chinese Medicine-Computerized Tongue Image Analysis System-Part 3: Colour Chart2020"},{"key":"B10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12882-021-02348-4","article-title":"Renal Outcomes of Idiopathic and Atypical Membranous Nephropathy in Adult Chinese Patients: a Single center Retrospective Cohort Study","volume":"22","author":"Jiang","year":"2021","journal-title":"BMC Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1053\/j.ajkd.2010.01.012","article-title":"Remission of Membranous Nephropathy after Therapy with Astragalus Membranaceus","volume":"55","author":"Leehey","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A New Equation to Estimate Glomerular Filtration Rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12882-015-0199-x","article-title":"Comparison of Tripterygium Wilfordii Multiglycosides and Tacrolimus in the Treatment of Idiopathic Membranous Nephropathy: a Prospective Cohort Study","volume":"16","author":"Liu","year":"2015","journal-title":"BMC Nephrol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.13288\/j.11-2166\/r.2021.19.005","article-title":"Development and Preliminary Optimization of the Dampness Syndrome Scale of Chinese Medicine","volume":"62","author":"Lu","year":"2021","journal-title":"J. Trandit. Chin. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"104190","DOI":"10.1016\/j.fitote.2019.104190","article-title":"The Genus Tripterygium: A Phytochemistry and Pharmacological Review","volume":"137","author":"Lv","year":"2019","journal-title":"Fitoterapia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s0272-6386(00)70316-7","article-title":"Distribution of Primary Renal Diseases Leading to End-Stage Renal Failure in the United States, Europe, and Australia\/New Zealand: Results from an International Comparative Study","volume":"35","author":"Maisonneuve","year":"2000","journal-title":"Am. J. Kidney Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"gmr7410","DOI":"10.4238\/gmr.15017410","article-title":"Effects and Mechanism of Tripterygium Wilfordii on Chronic Glomerulo Nephritis","volume":"15","author":"Pei","year":"2016","journal-title":"Genet. Mol. Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1016\/s0140-6736(15)60731-0","article-title":"Pathophysiological Advances in Membranous Nephropathy: Time for a Shift in Patient's Care","volume":"385","author":"Ronco","year":"2015","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5854710","DOI":"10.1155\/2018\/5854710","article-title":"Efficacy of Traditional Chinese Medicine Regimen Jian Pi Qu Shi Formula for Refractory Patients with Idiopathic Membranous Nephropathy: A Retrospective Case-Series Study","volume":"2018","author":"Shi","year":"2018","journal-title":"Evid. Based Complement. Alternat. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000437288","article-title":"Management of Membranous Nephropathy in Asia","volume":"1","author":"Xu","year":"2015","journal-title":"Kidney Dis. (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"A4","DOI":"10.1053\/j.ajkd.2016.06.011","article-title":"China Kidney Disease Network (CK-NET) 2014 Annual Data Report","volume":"69","author":"Zhang","year":"2017","journal-title":"Am. J. Kidney Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.3109\/13880209.2012.656847","article-title":"Sinomenium Acutum: a Review of Chemistry, Pharmacology, Pharmacokinetics, and Clinical Use","volume":"50","author":"Zhao","year":"2012","journal-title":"Pharm. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e030919","DOI":"10.1136\/bmjopen-2019-030919","article-title":"Comparative Efficacy of 13 Immunosuppressive Agents for Idiopathic Membranous Nephropathy in Adults with Nephrotic Syndrome: a Systematic Review and Network Meta-Analysis","volume":"9","author":"Zheng","year":"2019","journal-title":"BMJ Open"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.760482\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T08:52:39Z","timestamp":1641199959000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.760482\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,3]]},"references-count":23,"alternative-id":["10.3389\/fphar.2021.760482"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.760482","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,1,3]]},"article-number":"760482"}}